Beginner-friendly– category –
-
The Word “Vaccine” Breaks the Conversation: How Far Have Cancer Vaccines Actually Come?
The moment the word “vaccine” appears, conversations tend to heat up—and then collapse. This happens in infectious disease, and it also happens in cancer.In most cases, the problem is not a lack of knowledge. The problem is structural: w... -
Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Series Hub)
This series places women’s cancer risk on a single life-course map—from puberty and reproductive years to pregnancy/childbirth, the menopause transition, and postmenopause. We align breast, ovarian, and endometrial cancer considerations ... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 7)
Episode 7 | A Life-Course Prevention Playbook: Think in Life Events, Not Just Age—When to Seek Care, Screening Principles, and a Practical Summary Across this series, we placed breast, ovarian, and endometrial cancer risk on the same lif... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 6)
Episode 6 | Lifestyle and Women’s Cancer Risk: Weight, Activity, Alcohol, and Sleep—A Practical Plan to Lower Risk Without Chasing Perfection Hormonal milestones (menarche, pregnancy, menopause) shape women’s cancer risk over decades. Li... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 5)
Episode 5 | Perimenopause and Menopausal Symptoms: Balancing Cancer Risk, Quality of Life, and the Role of HRT Menopause is often described as “estrogen going down,” but lived experience is usually about something else: fluctuation. Hot ... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 4
Episode 4 | Endometrial Cancer, Hormone Balance, and Metabolic Health: The “Unopposed Estrogen” Intersection “My hormones feel off” is a common phrase—useful, but often too vague to drive action. Endometrial cancer (cancer of the uterine... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 3
Episode 3 | Ovarian Cancer: The “Silent Killer,” Reproductive Aging, and Why Detection Is Hard Ovarian cancer is sometimes called a “silent killer.” That phrase gained traction for two reasons: early symptoms are often not obvious, and t... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 2
Episode 2 | Breast Cancer Across Life Stages: Reading Risk Calmly with “Relative vs Absolute” Breast cancer is one of the most information-heavy topics in women’s health. Because it appears frequently in news and social media, it is also... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 1
Episode 1 | A Life-Course Map of Female Hormones: From Puberty to Post-Menopause Women’s health topics are often discussed in separate “boxes”: symptoms (PMS, menstrual pain, menopause) on one side, and diseases (breast cancer, ovarian c... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column B – A Practical ADC Strategy Checklist: Ten Questions for Pharma, Biotechs, Investors, and Advisors
In Column B, we translate the themes of this series into a practical checklist for people who must make decisions about ADCs in their daily work: executives and R&D / BD leaders at pharma companies, biotechs and start-ups developing ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column A – How Enhertu Reshaped the ADC Landscape: A Case Study in Design, Clinical Strategy, and Business Impact
In Column A, we focus on Enhertu, the ADC that appears repeatedly throughout this series, and ask a simple but far-reaching question:Why did this particular ADC become such a central reference point in the current ADC land grab? We will ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 7 – Synthesis: Where We Stand in 2025 and How ADCs May Evolve Toward the 2030s
In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—antibody, payload, linker, conjugation—and discussed what people mean by first-, second-... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 6 – Designing Oncology Portfolios Beyond ADCs: Positioning Bispecifics, Cell Therapies, and Radiopharmaceuticals
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—antibody, payload, linker, conjugation—and discussed what people mean by ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 5 – The Rise of China and Asian ADC Players: How the Global Map Is Being Redrawn and Where Japan Can Stand
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examined ADC design—antibody, payload, linker, conjugation—and discussed what people mean by ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 4 – How to Read ADC Deals: M&A, Licensing, Co-development, and CDMO Agreements
In Part 1 of this series, we looked at why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examined ADC design—antibody, payload, linker, conjugation—and discussed what people mean by... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 3 – Patent Cliffs and ADCs: Why Big Pharma Wants ADCs as Growth Engines for the Next Decade
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit within the broader landscape of cancer therapies, highlighting the paradigm shift triggered by Enhertu and the evolving player landscape. In Pa... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 2 – ADC Structure and Generational Shift: What “Second- and Third-generation” ADCs Really Mean After Enhertu
In Part 1 of this series, we asked why the ADC land grab is happening now, and we positioned ADCs within the broader landscape of cancer therapies, discussed the impact of Enhertu, and looked at how pharma, biotech, and investors are rea... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 1 – Why is There an ADC Land Grab Now? Introducing ADC’s Place in Cancer Therapy
Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncology and biopharma news. Multi-billion-dollar acquisitions, mega licensing deals, capacity expansions for ADC manufacturing, and the... -
Cancer Treatment Introductory–to–Basic Series – Overview
How to Read This 8-Part Series: Seeing the Bigger Picture of Cancer Care The “Cancer Treatment Introductory–to–Basic Series” consists of eight main articles that walk through the big picture of cancer care: overall structure, differences... -
Cancer Treatment Introductory–to–Basic Series – Part 8 (Final)
Life After Treatment and Survivorship: Shaping How You Live With and Beyond Cancer From Part 1 through Part 7 of this series, we have walked through the basics of cancer treatment: overall structure, differences in “curability” among can...
